Un­der hub-and-spoke biotech, se­r­i­al founders launch new start­up hop­ing to make gene ther­a­pies for the eye

In late Ju­ly, Sang­amo’s for­mer R&D chief Adri­an Woolf­son, who left the biotech when it split its R&D, launched his own gene ther­a­py out­fit. Re­play’s pri­ma­ry plat­form was an HSV vec­tor which, as a hub-and-spoke biotech, it said it was build­ing four dif­fer­ent com­pa­nies around.

Now, the first of those four com­pa­nies is out of the bag, with a co-found­ing team of four aca­d­e­mics who have deep biotech ex­pe­ri­ence. Named Eu­do­ra, the Re­play spoke com­pa­ny will go af­ter three eye dis­eases: re­tini­tis pig­men­tosa, Star­gardt dis­ease, and Ush­er syn­drome type 1B.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER